Amsterdam Molecular Therapeutics appoints chief medical officer

Dutch human gene therapy specialist hires Carlos Camozzi

Amsterdam Molecular Therapeutics (AMT), a Netherlands-based human gene therapy specialist, has appointed Carlos Camozzi as chief medical officer. He has more than 25 years of pharmaceutical industry experience, most recently within the orphan drug field. This includes overseeing product approvals at the European Medicines Agency and US Food and Drug Administration.

Camozzi joins AMT on 18 July from Orphan Europe, where he held the position of medical director for more than five years. Prior to this, he was a strategic development manager in the Molecular Pathology department of Basel University Hospital, Switzerland. In this role, he interacted with both pharmaceutical customers and regulatory authorities.

From 2001–2005, Camozzi was md of MCP-medeor consulting pharma, where he helped design preclinical and clinical development programmes for pharmaceutical and healthcare products.

Dr Camozzi started his career in South America holding roles at Lederle/American Cyanamid and F Hoffmann La-Roche.

You may also like

Research & Development

AMT receives €1.1m funding as part of EU consortium grant

For Acute Intermittent Porphyria (AIP) gene therapy
Manufacturing

AMT to supply manufacturing for gene therapy product

For a rare genetic disorder in children
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

PhoreMost announces PMC-001 as lead oncology programme

The biotech will advance the small molecule towards Phase I trials, positioning it for the treatment of primary and secondary brain cancers. Dr Gabriel Fox will also join the company as Consulting Chief Medical Officer to lead the clinical development of the molecule
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Where nanoengineering meets drug formulation

How Nanexa is turning short-acting drugs into long-acting injectables
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Subscribe now